abbvie

AbbVie posts strong Q4 results

pharmafile | February 1, 2016 | News story | Sales and Marketing AbbVie, Humira, Viekira Pak 

AbbVie managed to meet or beat analysts’ expectations in its Q4 financial results report, with extremely strong Humira sales contributing to adjusted global revenues of $6.4 billion for the quarter and $22.82 billion for the whole of 2015- up 22.1% on the previous year

Hepatitis C regimen Viekira Pak also contributed $554 million in the fourth quarter, and AbbVie pointed to strong operational growth from Duodopa, Creon and Lupron. The Illinois, US-based company also found significant efficiencies in selling, general and administration costs- reducing its bill 48% to $1.74 billion from $3.34 billion.

Adjusted earnings per share for 2015 were $4.29, up 29% from the $3.32 of 2014- a year in which profits were hit by administration costs from the aborted Shire takeover.

The strong results led AbbVie to confidently predict it would be amongst the industry leaders for growth in 2016.  

“AbbVie delivered strong performance in 2015, exceeding original sales, margin expansion, and earnings projections for the year,” says Richard Gonzalez, chairman and chief executive officer, AbbVie. “We achieved significant growth in 2015, and expect to continue building on that momentum in 2016 with another year of strong performance.”

Joel Levy

Related Content

AbbVie invests €150m in new R&D facility in Germany

AbbVie has announced that it is investing approximately €150m in its second largest research and …

Medincell and AbbVie enter agreement for development of next-generation injectables

Medincell and AbbVie have announced that they have entered into a collaboration to co-develop and …

AbbVie to acquire Landos Biopharma for approximately $137.5m

AbbVie and Landos Biopharma have announced that they have entered into a definitive agreement under …

Latest content